Difficulty of Adjuvant Chemotherapy Administration in Patients with Biliary Tract Cancer

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2023 Nov 24

PMID 37999810

Authors

Tatsuaki Sumiyoshi

Kenichiro Uemura

Ryuta Shintakuya

Kenjiro Okada

Kenta Baba

Takumi Harada

Masahiro Serikawa

Yasutaka Ishii

Shinya Nakamura

Koji Arihiro

Yoshiaki Murakami

Shinya Takahashi

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to elucidate the difficulty of adjuvant chemotherapy administration in patients with biliary tract carcinoma (BTC).

Methods: Clinical data of patients with BTC who underwent curative-intent surgery were retrospectively analyzed. The eligible patients were stratified into two groups according to the presence or absence of adjuvant chemotherapy administration (adjuvant and non-adjuvant groups), and the clinicopathological features were compared between the two groups. The ratios of adjuvant chemotherapy administration were investigated in each surgical procedure. Independent factors associated with no administration of adjuvant chemotherapy were analyzed using multivariate analyses.

Results: Among 168 eligible patients, 141 (83.9%) received adjuvant chemotherapy (adjuvant group), while 27 (16.1%) did not (non-adjuvant group). The most common surgical procedure was pancreaticoduodenectomy in the adjuvant group, and it was hepatectomy with extrahepatic bile duct resection (BDR) in the non-adjuvant group, respectively. The rate of no adjuvant chemotherapy was significantly higher in patients who underwent hepatectomy with BDR than in those who underwent other surgeries (p < 0.001). The most common cause of no adjuvant chemotherapy was bile leak in 12 patients, which occurred after hepatectomy with BDR in ten patients. Multivariate analyses revealed that hepatectomy with BDR and preoperative anemia were independently associated with no adjuvant chemotherapy (p < 0.001 and p < 0.001, respectively).

Conclusions: Hepatectomy with BDR and subsequent refractory bile leak can be the obstacle to adjuvant chemotherapy administration in patients with BTC.

References

Jarnagin W, Fong Y, DeMatteo R, Gonen M, BURKE E, Bodniewicz BS J . Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001; 234(4):507-17; discussion 517-9. PMC: 1422074. DOI: 10.1097/00000658-200110000-00010. View

de Groen P, Gores G, Larusso N, Gunderson L, Nagorney D . Biliary tract cancers. N Engl J Med. 1999; 341(18):1368-78. DOI: 10.1056/NEJM199910283411807. View

Ilyas S, Khan S, Hallemeier C, Kelley R, Gores G . Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2017; 15(2):95-111. PMC: 5819599. DOI: 10.1038/nrclinonc.2017.157. View

Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas H . Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37(6):806-13. DOI: 10.1016/s0168-8278(02)00297-0. View

Taylor-Robinson S, Toledano M, Arora S, Keegan T, Hargreaves S, Beck A . Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001; 48(6):816-20. PMC: 1728314. DOI: 10.1136/gut.48.6.816. View

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N . Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg. 2013; 17(8):1429-39. DOI: 10.1007/s11605-013-2251-0. View

Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Nomura T . Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer. 2009; 116(2):400-5. DOI: 10.1002/cncr.24766. View

Blom D, Schwartz S . Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg. 2001; 136(2):209-15. DOI: 10.1001/archsurg.136.2.209. View

Kamposioras K, Anthoney A, Fernandez Moro C, Cairns A, Smith A, Liaskos C . Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg. 2013; 101(2):89-99. DOI: 10.1002/bjs.9367. View

10.

Jang J, Kim S, Park D, Ahn Y, Yoon Y, Choi M . Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2004; 241(1):77-84. PMC: 1356849. DOI: 10.1097/01.sla.0000150166.94732.88. View

11.

Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J . Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005; 137(4):396-402. DOI: 10.1016/j.surg.2004.10.008. View

12.

Kobayashi A, Miwa S, Nakata T, Miyagawa S . Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg. 2009; 97(1):56-64. DOI: 10.1002/bjs.6788. View

13.

Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A . Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017; 104(4):426-433. DOI: 10.1002/bjs.10452. View

14.

Khan S, Davidson B, Goldin R, Heaton N, Karani J, Pereira S . Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; 61(12):1657-69. DOI: 10.1136/gutjnl-2011-301748. View

15.

Ebata T, Kosuge T, Hirano S, Unno M, Yamamoto M, Miyazaki M . Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg. 2013; 101(2):79-88. DOI: 10.1002/bjs.9379. View

16.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H . Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg. 2009; 250(6):950-6. DOI: 10.1097/sla.0b013e3181b0fc8b. View

17.

Primrose J, Fox R, Palmer D, Malik H, Prasad R, Mirza D . Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20(5):663-673. DOI: 10.1016/S1470-2045(18)30915-X. View

18.

Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E . A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Ann Surg. 2018; 270(2):230-237. DOI: 10.1097/SLA.0000000000002865. View

19.

Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T . Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401(10372):195-203. DOI: 10.1016/S0140-6736(22)02038-4. View

20.

Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M . Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010; 252(1):115-23. DOI: 10.1097/SLA.0b013e3181e463a7. View